Literature DB >> 31203232

Dysferlin deficiency alters lipid metabolism and remodels the skeletal muscle lipidome in mice.

Vanessa R Haynes1, Stacey N Keenan1, Jackie Bayliss1, Erin M Lloyd2, Peter J Meikle3, Miranda D Grounds4, Matthew J Watt5.   

Abstract

Defects in the gene coding for dysferlin, a membrane-associated protein, affect many tissues, including skeletal muscles, with a resultant myopathy called dysferlinopathy. Dysferlinopathy manifests postgrowth with a progressive loss of skeletal muscle function, early intramyocellular lipid accumulation, and a striking later replacement of selective muscles by adipocytes. To better understand the changes underpinning this disease, we assessed whole-body energy homeostasis, skeletal muscle fatty acid metabolism, lipolysis in adipose tissue, and the skeletal muscle lipidome using young adult dysferlin-deficient male BLAJ mice and age-matched C57Bl/6J WT mice. BLAJ mice had increased lean mass and reduced fat mass associated with increased physical activity and increased adipose tissue lipolysis. Skeletal muscle fatty acid metabolism was remodeled in BLAJ mice, characterized by a partitioning of fatty acids toward storage rather than oxidation. Lipidomic analysis identified marked changes in almost all lipid classes examined in the skeletal muscle of BLAJ mice, including sphingolipids, phospholipids, cholesterol, and most glycerolipids but, surprisingly, not triacylglycerol. These observations indicate that an early manifestation of dysferlin deficiency is the reprogramming of skeletal muscle and adipose tissue lipid metabolism, which is likely to contribute to the progressive adverse histopathology in dysferlinopathies.
Copyright © 2019 Haynes et al.

Entities:  

Keywords:  BLAJ mice; adipose tissue; dysferlin; fatty acid metabolism; insulin resistance; lipidomics; lipolysis

Mesh:

Substances:

Year:  2019        PMID: 31203232      PMCID: PMC6672035          DOI: 10.1194/jlr.M090845

Source DB:  PubMed          Journal:  J Lipid Res        ISSN: 0022-2275            Impact factor:   5.922


  61 in total

1.  Ciliary neurotrophic factor prevents acute lipid-induced insulin resistance by attenuating ceramide accumulation and phosphorylation of c-Jun N-terminal kinase in peripheral tissues.

Authors:  Matthew J Watt; Andrea Hevener; Graeme I Lancaster; Mark A Febbraio
Journal:  Endocrinology       Date:  2006-01-05       Impact factor: 4.736

2.  Assessment of skeletal muscle triglyceride content by (1)H nuclear magnetic resonance spectroscopy in lean and obese adolescents: relationships to insulin sensitivity, total body fat, and central adiposity.

Authors:  Ranjana Sinha; Sylvie Dufour; Kitt Falk Petersen; Vincent LeBon; Staffan Enoksson; Yong-Zhan Ma; Mary Savoye; Douglas L Rothman; Gerald I Shulman; Sonia Caprio
Journal:  Diabetes       Date:  2002-04       Impact factor: 9.461

3.  Mechanism by which fatty acids inhibit insulin activation of insulin receptor substrate-1 (IRS-1)-associated phosphatidylinositol 3-kinase activity in muscle.

Authors:  Chunli Yu; Yan Chen; Gary W Cline; Dongyan Zhang; Haihong Zong; Yanlin Wang; Raynald Bergeron; Jason K Kim; Samuel W Cushman; Gregory J Cooney; Bronwyn Atcheson; Morris F White; Edward W Kraegen; Gerald I Shulman
Journal:  J Biol Chem       Date:  2002-11-14       Impact factor: 5.157

4.  Effects of acute changes of plasma free fatty acids on intramyocellular fat content and insulin resistance in healthy subjects.

Authors:  G Boden; B Lebed; M Schatz; C Homko; S Lemieux
Journal:  Diabetes       Date:  2001-07       Impact factor: 9.461

5.  Fat mobilization in adipose tissue is promoted by adipose triglyceride lipase.

Authors:  Robert Zimmermann; Juliane G Strauss; Guenter Haemmerle; Gabriele Schoiswohl; Ruth Birner-Gruenberger; Monika Riederer; Achim Lass; Georg Neuberger; Frank Eisenhaber; Albin Hermetter; Rudolf Zechner
Journal:  Science       Date:  2004-11-19       Impact factor: 47.728

6.  Defective membrane repair in dysferlin-deficient muscular dystrophy.

Authors:  Dimple Bansal; Katsuya Miyake; Steven S Vogel; Séverine Groh; Chien-Chang Chen; Roger Williamson; Paul L McNeil; Kevin P Campbell
Journal:  Nature       Date:  2003-05-08       Impact factor: 49.962

7.  Disruption of muscle membrane and phenotype divergence in two novel mouse models of dysferlin deficiency.

Authors:  Mengfatt Ho; Cristina M Post; Leah R Donahue; Hart G W Lidov; Roderick T Bronson; Holly Goolsby; Simon C Watkins; Gregory A Cox; Robert H Brown
Journal:  Hum Mol Genet       Date:  2004-07-14       Impact factor: 6.150

8.  Ceramide content is increased in skeletal muscle from obese insulin-resistant humans.

Authors:  John M Adams; Thongchai Pratipanawatr; Rachele Berria; Elaine Wang; Ralph A DeFronzo; M Cameron Sullards; Lawrence J Mandarino
Journal:  Diabetes       Date:  2004-01       Impact factor: 9.461

9.  Dysferlin is a plasma membrane protein and is expressed early in human development.

Authors:  L V Anderson; K Davison; J A Moss; C Young; M J Cullen; J Walsh; M A Johnson; R Bashir; S Britton; S Keers; Z Argov; I Mahjneh; F Fougerousse; J S Beckmann; K M Bushby
Journal:  Hum Mol Genet       Date:  1999-05       Impact factor: 6.150

10.  Ultrastructural changes in dysferlinopathy support defective membrane repair mechanism.

Authors:  G Cenacchi; M Fanin; L B De Giorgi; C Angelini
Journal:  J Clin Pathol       Date:  2005-02       Impact factor: 3.411

View more
  6 in total

1.  Blockade of Hemichannels Normalizes the Differentiation Fate of Myoblasts and Features of Skeletal Muscles from Dysferlin-Deficient Mice.

Authors:  Luis A Cea; Gabriela Fernández; Guisselle Arias-Bravo; Mario Castillo-Ruiz; Rosalba Escamilla; María C Brañes; Juan C Sáez
Journal:  Int J Mol Sci       Date:  2020-08-21       Impact factor: 5.923

2.  UCP1 Knockin Induces Lipid Dynamics and Transcriptional Programs in the Skeletal Muscles of Pigs.

Authors:  Ziye Xu; Wentao Chen; Liyi Wang; Wenjing You; Yanfang Wang; Yizhen Wang; Jianguo Zhao; Tizhong Shan
Journal:  Front Cell Dev Biol       Date:  2022-01-12

3.  4-Phenylbutyrate restores localization and membrane repair to human dysferlin mutations.

Authors:  Kana Tominaga; Naoomi Tominaga; Eric O Williams; Laura Rufibach; Verena Schöwel; Simone Spuler; Mohan Viswanathan; Leonard P Guarente
Journal:  iScience       Date:  2021-12-20

4.  Therapeutic Benefit of Galectin-1: Beyond Membrane Repair, a Multifaceted Approach to LGMD2B.

Authors:  Mary L Vallecillo-Zúniga; Peter Daniel Poulson; Jacob S Luddington; Christian J Arnold; Matthew Rathgeber; Braden C Kartchner; Spencer Hayes; Hailie Gill; Jonard C Valdoz; Jonathan L Spallino; Seth Garfield; Ethan L Dodson; Connie M Arthur; Sean R Stowell; Pam M Van Ry
Journal:  Cells       Date:  2021-11-17       Impact factor: 6.600

5.  Cholesterol absorption blocker ezetimibe prevents muscle wasting in severe dysferlin-deficient and mdx mice.

Authors:  Zoe White; Marine Theret; Nadia Milad; Lin Wei Tung; William Wei-Han Chen; Martin G Sirois; Fabio Rossi; Pascal Bernatchez
Journal:  J Cachexia Sarcopenia Muscle       Date:  2021-12-19       Impact factor: 12.910

Review 6.  Mouse models for muscular dystrophies: an overview.

Authors:  Maaike van Putten; Erin M Lloyd; Jessica C de Greef; Vered Raz; Raffaella Willmann; Miranda D Grounds
Journal:  Dis Model Mech       Date:  2020-02-21       Impact factor: 5.758

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.